Vericel : to Host Fourth-Quarter 2014 Earnings Call on March 23, 2015
March 21, 2015 at 08:11 pm EDT
Share
What:
Vericel, Inc., Fourth Quarter 2014 Earnings Call
When:
Monday, March 23, 2015 at 4:30pm (EDT)
Where:
http://investors.vcel.com/events.cfm
How:
-- The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm.
Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary.
-- To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation fourth quarter 2014 investor conference call.
If calling from outside the U.S., please use the international phone number (253) 237-1173.
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
VERICEL CORPORATION 
